Published in J Virol on November 01, 2000
AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci U S A (2009) 1.46
Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica (2010) 1.42
Dynamic chromatin boundaries delineate a latency control region of Epstein-Barr virus. J Virol (2004) 1.33
Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. J Virol (2010) 1.27
Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol (2009) 1.16
Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol (2003) 1.15
Alternatively initiated gene 50/RTA transcripts expressed during murine and human gammaherpesvirus reactivation from latency. J Virol (2008) 1.05
Epigenetic regulation of varicella-zoster virus open reading frames 62 and 63 in latently infected human trigeminal ganglia. J Virol (2006) 1.02
The Epstein-Barr virus lytic cycle activator Zta interacts with methylated ZRE in the promoter of host target gene egr1. J Gen Virol (2009) 0.98
Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing. J Virol (2007) 0.95
Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines. J Virol (2006) 0.94
Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation. Curr Opin Virol (2013) 0.91
Unbiased mutagenesis of MHV68 LANA reveals a DNA-binding domain required for LANA function in vitro and in vivo. PLoS Pathog (2012) 0.89
Modeling early Epstein-Barr virus infection in Drosophila melanogaster: the BZLF1 protein. Genetics (2005) 0.88
Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle. J Virol (2011) 0.87
Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B-lymphoblastoid cell lines. J Virol (2004) 0.87
The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1. J Virol (2013) 0.83
Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency. J Virol (2011) 0.82
trans-Repression of protein expression dependent on the Epstein-Barr virus promoter Wp during latency. J Virol (2011) 0.80
EBV in Hodgkin Lymphoma. Mediterr J Hematol Infect Dis (2009) 0.78
A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A (1992) 29.51
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet (1998) 13.27
Methylation-induced repression--belts, braces, and chromatin. Cell (1999) 9.89
CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev (1989) 5.00
Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science (1994) 4.87
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
EBV persistence in memory B cells in vivo. Immunity (1998) 4.44
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A (1994) 3.88
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol (1990) 3.51
Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci U S A (1990) 3.29
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol (1991) 3.03
Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol (1992) 2.95
Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes. Proc Natl Acad Sci U S A (1989) 2.88
Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer (1978) 2.81
EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol (1991) 2.70
Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci U S A (1991) 2.61
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci U S A (1991) 2.54
Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol (1997) 2.53
Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc Natl Acad Sci U S A (1991) 2.40
Creation of genomic methylation patterns. Nat Genet (1996) 2.15
The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J (1994) 2.07
5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol (1989) 1.99
Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci U S A (1995) 1.89
Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol (1984) 1.88
The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol (1989) 1.77
oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol (1996) 1.67
Conservation and progressive methylation of Epstein-Barr viral DNA sequences in transformed cells. J Virol (1981) 1.59
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene (1998) 1.58
Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood (1998) 1.55
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood (1992) 1.51
Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol Cell Biol (1995) 1.45
Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5'-flanking region. J Virol (1991) 1.33
Host cell phenotype-dependent methylation patterns of Epstein-Barr virus DNA. J Gen Virol (1991) 1.30
Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines. J Virol (1992) 1.30
Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol (1997) 1.28
Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. J Virol (1999) 1.28
Cellular and viral DNA hypomethylation associated with induction of Epstein-Barr virus lytic cycle. Proc Natl Acad Sci U S A (1985) 1.23
Cytosine methylation of repeated sequences in eukaryotes: the role of DNA pairing. Trends Biochem Sci (1998) 1.21
Binding sites in mammalian genes and viral gene regulatory regions recognized by methylated DNA-binding protein. Nucleic Acids Res (1990) 1.20
Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood (1997) 1.18
Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp). J Virol (1997) 1.16
Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J Virol (1999) 1.13
B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1. J Virol (1997) 1.12
CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood (1996) 1.11
Significant potential secondary structures in the Epstein-Barr virus genome. Proc Natl Acad Sci U S A (1986) 1.09
The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol (1998) 1.06
The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J Virol (2000) 1.04
Host-cell-phenotype-dependent control of the BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6. Proc Natl Acad Sci U S A (1992) 1.03
CpG methylation of viral DNA in EBV-associated tumours. Int J Cancer (1990) 0.98
Characterisation of regulatory sequences at the Epstein-Barr virus BamHI W promoter. Virology (1998) 0.96
The activity of the Epstein-Barr virus BamHI W promoter in B cells is dependent on the binding of CREB/ATF factors. J Gen Virol (2000) 0.96
Specific methylation patterns in two control regions of Epstein-Barr virus latency: the LMP-1-coding upstream regulatory region and an origin of DNA replication (oriP). J Virol (1998) 0.93
A methylation-responsive MDBP/RFX site is in the first exon of the collagen alpha2(I) promoter. J Biol Chem (1999) 0.91
Methylation-dependent and -independent DNA binding of nuclear factor EF-C. Virology (1991) 0.89
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med (1996) 3.94
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol (1988) 3.84
Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (1991) 3.61
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol (1990) 3.51
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol (1999) 3.36
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol (1992) 2.83
Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer (1978) 2.81
Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med (1997) 2.76
Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res (1981) 2.74
Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax (2001) 2.74
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity. Int J Cancer (1982) 2.55
Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med (1988) 2.52
Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) (2002) 2.38
HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science (1993) 2.28
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer (1985) 2.23
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med (1994) 2.04
T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol (1984) 2.01
Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer (1989) 1.97
HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells. Nature (1980) 1.90
Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet (1986) 1.88
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol (1993) 1.88
Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature (1985) 1.86
Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med (1996) 1.85
Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol (1997) 1.78
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol (1993) 1.77
Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer (1989) 1.76
EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol (2001) 1.75
Human epithelial cell expression of an Epstein-Barr virus receptor. J Gen Virol (1987) 1.73
Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc Natl Acad Sci U S A (2006) 1.70
Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J Gen Virol (1991) 1.70
Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. J Natl Cancer Inst (1986) 1.69
Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology (1996) 1.66
Memory T cells constitute a subset of the human CD8+CD45RA+ pool with distinct phenotypic and migratory characteristics. J Immunol (2001) 1.66
Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer (1986) 1.62
Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer (1985) 1.62
The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J Virol (1992) 1.61
Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J Immunol (1987) 1.60
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol (1993) 1.58
New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol (1987) 1.58
In vitro analysis of the Epstein-Barr virus: host balance in long-term renal allograft recipients. Int J Cancer (1985) 1.55
Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis. Eur J Immunol (1987) 1.55
Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology (1992) 1.53
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood (1992) 1.51
Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leukocyte cultures. Int J Cancer (1979) 1.51
CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol (2005) 1.49
Definition of nitrite and nitrate response elements at the anaerobically inducible Escherichia coli nirB promoter: interactions between FNR and NarL. Mol Microbiol (1993) 1.42
Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature (1982) 1.39
Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med (1993) 1.38
Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer (1984) 1.37
Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol (1988) 1.37
Observations on the type of infection by Epstein-Barr virus in peripheral lymphoid cells of patients with infectious mononucleosis. Int J Cancer (1974) 1.37
Interconversion of the DNA-binding specificities of two related transcription regulators, CRP and FNR. Mol Microbiol (1990) 1.34
Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood (1996) 1.32
Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro. Eur J Immunol (1981) 1.30
Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1. J Virol (1999) 1.28
Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol (1992) 1.28
The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. J Gen Virol (1991) 1.27
Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer (2007) 1.26
Orientation of functional activating regions in the Escherichia coli CRP protein during transcription activation at class II promoters. Nucleic Acids Res (1996) 1.25
Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med (1995) 1.25
The Epstein-Barr virus as a model of virus-host interactions. Br Med Bull (1985) 1.24
Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2. Eur J Immunol (1982) 1.24
Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J Immunol (2000) 1.23
Characterization of the HLA-A2.2 subtype: T cell evidence for further heterogeneity. Immunogenetics (1985) 1.20
Spontaneous outgrowth of Epstein-Barr virus-positive B-cell lines from circulating human B cells of different buoyant densities. Int J Cancer (1991) 1.20
Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus). II. EB virus in a cell line from an animal with reticuloproliferative disease. Int J Cancer (1973) 1.19
Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals. J Virol (1996) 1.17
Long-term T-cell-mediated immunity to Epstein-Barr virus in man. IV. Development of T-cell memory in convalescent infectious mononucleosis patients. Int J Cancer (1980) 1.16
High resolution EEG: 124-channel recording, spatial deblurring and MRI integration methods. Electroencephalogr Clin Neurophysiol (1994) 1.15
Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C. J Virol (1991) 1.14
Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization. Int J Cancer (1991) 1.14
Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J Virol (1999) 1.13
A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int J Cancer (1983) 1.13
Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinants. Eur J Immunol (1981) 1.12
Epstein-Barr virus: LMP1 masquerades as an active receptor. Curr Biol (1998) 1.11
Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins. J Virol (1989) 1.11
Sequential appearance of Epstein-Barr virus nuclear and lymphocyte-detected membrane antigens in B cell transformation. Nature (1981) 1.11
Analysis of VH genes used by neoplastic B cells in endemic Burkitt's lymphoma shows somatic hypermutation and intraclonal heterogeneity. Blood (1995) 1.11
Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes. Eur J Immunol (1987) 1.10
Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int J Cancer (1981) 1.09